NASDAQ:DBVT DBV Technologies Q4 2024 Earnings Report $9.87 +0.15 (+1.54%) Closing price 03:59 PM EasternExtended Trading$9.84 -0.03 (-0.35%) As of 05:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. ProfileEarnings HistoryForecast DBV Technologies EPS ResultsActual EPS-$1.10Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/ADBV Technologies Revenue ResultsActual Revenue$0.51 millionExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/ADBV Technologies Announcement DetailsQuarterQ4 2024Date4/11/2025TimeAfter Market ClosesConference Call DateN/AConference Call TimeN/AConference Call ResourcesPress ReleaseEarnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release DBV Technologies Earnings HeadlinesQ3 EPS Estimates for DBV Technologies Cut by Lifesci CapitalAugust 3 at 2:49 AM | americanbankingnews.comHC Wainwright Predicts Reduced Earnings for DBV TechnologiesAugust 3 at 2:49 AM | americanbankingnews.comThe Coin That Could Define Trump’s Crypto PresidencyWhen Trump returned to office, one of his first moves was to tap PayPal’s former COO, David Sacks, as a top advisor on crypto and AI. That alone signaled a shift. But insiders close to D.C. aren’t just talking crypto policy—they’re quietly buying something most retail investors have missed. While the crowd chases Bitcoin to $150,000, Weiss Ratings expert Juan Villaverde believes a different coin—already backed by giants like Google, Visa, and PayPal—could soon become crypto’s “Third Giant.”August 6 at 2:00 AM | Weiss Ratings (Ad)DBV Technologies S.A.: DBV Technologies Reports Second Quarter and Half-Year 2025 Financial ResultsJuly 30, 2025 | finanznachrichten.deDBV Technologies Reports Progress in Clinical Trials and FinancingJuly 29, 2025 | tipranks.comDBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the ReportJuly 29, 2025 | globenewswire.comSee More DBV Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like DBV Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on DBV Technologies and other key companies, straight to your email. Email Address About DBV TechnologiesDBV Technologies (NASDAQ:DBVT), a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. The company's earlier stage research programs includes vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, it develops Viaskin technology platform, a platform to potentially treat food allergy. The company has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Montrouge, France.View DBV Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Rivian Takes Earnings Hit—R2 Could Be the Stock's 2026 LifelinePalantir Stock Soars After Blowout Earnings ReportVertical Aerospace's New Deal and Earnings De-Risk ProductionAmazon's Earnings: What Comes Next and How to Play ItApple Stock: Big Earnings, Small Move—Time to Buy?Why Robinhood Just Added Upside Potential After a Q2 Earnings DipMicrosoft Blasts Past Earnings—What’s Next for MSFT? Upcoming Earnings Gilead Sciences (8/7/2025)Monster Beverage (8/7/2025)Constellation Energy (8/7/2025)Becton, Dickinson and Company (8/7/2025)Brookfield (8/7/2025)Canadian Natural Resources (8/7/2025)ConocoPhillips (8/7/2025)Diageo (8/7/2025)EOG Resources (8/7/2025)Flutter Entertainment (8/7/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
